Drug Trial Radar · NCT01436968
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
711
Planned (sponsor's estimate)
Start
Sep 2011
Primary completion
Aug 2024
Study completion Dec 2030
Sponsor
- Lead sponsor
- Candel Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.
Conditions
- Prostate Cancer
Interventions
Aglatimagene besadenovec + valacyclovirBiological
Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Placebo + valacyclovirBiological
Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.Time frame: Assessed at each visit every 6 months through year 5 until event occurs.
Locations
73 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona
Arizona Urology Specialists
Glendale, Arizona
Arizona Center for Cancer Care - Peoria
Peoria, Arizona
Arizona Center for Cancer Care - Deer Valley
Phoenix, Arizona
Arizona Oncology Services Foundation
Phoenix, Mesa, Scottsdale, Sedona, Arizona
Arizona Center for Cancer Care - Osborne
Scottsdale, Arizona
Arizona Center for Cancer Care - Shea
Scottsdale, Arizona
Arizona Center for Cancer Care - Surprise
Surprise, Arizona
Southern Arizona VA Health Care System
Tucson, Arizona
VA Northern California Health Care System
Mather, California
Precision Radiation Oncology
Tustin, California
Valley View Hospital
Glenwood Springs, Colorado
Colorado Clinical Research
Lakewood, Colorado
Advanced Urology
Parker, Colorado
Sibley Memorial Hospital
Washington D.C., District of Columbia
21st Century Oncology
Fort Lauderdale, Florida
21st Century Oncology
Lakewood Rch, Florida
21st Century Oncology
Naples, Florida
21st Century Oncology
Plantation, Florida
Clinical Research Center of Florida
Pompano Beach, Florida
James A. Haley Veteran's Hospital
Tampa, Florida
Florida Urology Partners
Tampa, Florida
Jesse Brown VA Medical Center
Chicago, Illinois
The University of Chicago
Chicago, Illinois
Silver Cross Hospital
New Lenox, Illinois
Southeast Louisiana Veterans Health Care System
New Orleans, Louisiana
VA Maryland Health Care System
Baltimore, Maryland
Chesapeake Urology Research Associates
Baltimore, Maryland
The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland
University of Massachusetts Medical School
Worcester, Massachusetts
Kansas City VA Medical Center
Kansas City, Missouri
Adult & Pediatric Urology, P.C.
Omaha, Nebraska
Sheldon Freedman MD, Ltd.
Las Vegas, Nevada
VA Sierra Nevada Health Care System
Reno, Nevada
New Jersey Urology - Cherry Hill
Cherry Hill, New Jersey
New Jersey Urology - Englewood
Englewood, New Jersey
New Jersey Urology - Milburn
Millburn, New Jersey
New Jersey Urology - Saddle Brook
Saddle Brook, New Jersey
New Jersey Urology - West Orange
West Orange, New Jersey
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.